ClinicalTrials.gg
RecruitingNCT06569953Updated Jun 27, 2025

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

A Phase 4 interventional study of Liposomal bupivacaine and Bupivacaine Hydrochloride in Acute Pain, Chronic Pain and Postoperative Pain, sponsored by The Second Affiliated Hospital of Chongqing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by The Second Affiliated Hospital of Chongqing Medical University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing Liposomal Bupivacaine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. Liposomal Bupivacaine · Acute Pain.

Planned enrollment
2nd of 12
284 · median 89
Started
2024
with 1 other
Phase 4
11 of 12
3 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
The Second Affiliated Hospital of Chongqing Medical University

Among the 12 studies testing Liposomal Bupivacaine in Acute Pain, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2024, is one of 11 in phase 4, and was the 11th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 12 studies testing Liposomal Bupivacaine in Acute Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Liposomal Bupivacaine in Acute Pain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.

Read the detailed description

Researchers will compare liposomal bupivacaine to bupivacaine to see if liposomal bupivacaine works better to treat acute and chronic pain after video-assisted thoracoscopic lobectomy.Participants will:1.Received liposomal bupivacaine or bupivacaine paravertebral block before surgery. 2.Keep a diary of their pain scores within 30min after recovery from anesthesia and 6h, 12h, 24h, 48h, 72h and 90d after the beginning of injection of experimental drugs.

03

Conditions studied

  • Acute Pain
  • Chronic Pain
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia.
  • Participants were 18 years or older.
  • 18 kg/m2≤≤30 kg/m2
  • Participants with American Society of Anesthesiology (ASA) physical status I-III.
  • Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the form voluntarily.

Exclusion criteria

Exclusion Criteria:

  • with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), (NYHA) functional class III/IV,Ischemic stroke.
  • with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment.
  • with sensory disorders such as hyperalgesia.
  • with other bodily pain.
  • allergy to amide-type local anesthetics or any of the trial drugs
  • taking drugs that affect liver metabolism,,benzodiazepines,non-steroidal anti-inflammatory drugs(NSAIDs),opioid agonist-antagonist,central-alpha 2-agonists,anticonvulsants,antidepressants within 72h.
  • with a history of alcohol or opioid abuse.
  • who were pregnant or lactating.
  • who were currently included in another clinical study within 3 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
284 participants (estimated)

Study arms

  • Experimental
    intervention (liposomal bupivacaine)

    Participants randomized to the intervention arm received liposomal bupivacaine for paravertebral block before surgery.

    Drug: Liposomal bupivacaine

  • Active comparator
    control (bupivacaine hydrochloride)

    Participants randomized to the intervention arm received bupivacaine hydrochloride for paravertebral block before surgery.

    Drug: Bupivacaine Hydrochloride

Interventions

  • Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)

06

What researchers measure

Primary outcomes

  1. Area under the movement-evoked pain intensity-time curve

    Area under the pain intensity-time curve in the movement (or coughing) state within 72h after the intervention.

    Time frame: from 0-72 hours after the intervention

  2. The incidence of chronic postoperative pain

    The incidence of chronic postoperative pain at 90 days

    Time frame: postoperative day (POD) 90

Secondary outcomes

  1. Area under the rest pain intensity-time curve

    Area under the pain intensity-time curve at rest within 72h after the intervention.

    Time frame: from 0-72 hours after the intervention

  2. Movement-evoked pain score

    Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)

    Time frame: 30 minutes after recovery from anesthesia,6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention

  3. Pain score at rest

    Use pain Numeric Rating Scale(NRS) to evaluate the pain score at rest at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)

    Time frame: 30 minutes after recovery from anesthesia,6 hours,12hours, 24hours , 48hours and 72 hours after the intervention

  4. Proportion of participants who did not use rescue analgesia

    Proportion of participants who did not use rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after the intervention.

    Time frame: from 0-72 hours after the intervention

  5. The cumulative dosage of rescue analgesia

    The cumulative dosage of rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72hours and 0-72hours after the intervention.

    Time frame: from 0-72 hours after the intervention

  6. The time of first use of rescue analgesia

    The time of first use of rescue analgesia

    Time frame: from 0-72 hours after the intervention

  7. First time out-of-bed

    Time of participant's first out-of-bed activity after surgery

    Time frame: From date of surgery until the date of first out-of-bed,assessed up to 7 days

  8. Length of hospital stay

    Duration of participants from hospital admission to hospital discharge

    Time frame: From date of surgery until the date of first hospital discharge,assessed up to 1 months

  9. Chronic pain score

    Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score and rest pain score at 90 days after surgery.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)

    Time frame: postoperative day (POD) 90

  10. Score of satisfaction with analgesia

    At 72 hours after the intervention,the participants rated the satisfaction with analgesia.Satisfaction rating scale 0-5,where 0 was poor drug effectiveness, and 5 was excellent drug efficacy)

    Time frame: At 72 hours after the intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2025, 12 months after the start.

Of 79 non-industry phase 4 interventional studies under Acute Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 32. This study's planned 12 months is below that.

Counting every sponsor, half of 84 studies reached it within 19 months; a quarter within 9 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 26, 2024
StartActual
Aug 26, 2024
Primary completionEst.
Aug 31, 2025
CompletionEst.
Aug 31, 2025
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06569953
Collaborators
People's Hospital of Chongqing, LanZhou University, Xiangya Hospital of Central South University, Shapingba District People's Hospital of Chongqing
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Aug 26, 2024
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Jun 27, 2025

Study contacts

He Huang, ph.D
Contact
huanghe@cqmu.edu.cn
86+13708385559
Guangyou Duan, ph.D
Contact
duangy@hospital.cqmu.edu.cn
86+18323376014
He Huang, ph.D
study chair · The Second Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion